Cyclacel Pharmaceuticals Files 8-K Report
Ticker: BGMSP · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1130166
Sentiment: neutral
Topics: 8-K, material-agreement, financials
TL;DR
Cyclacel Pharma filed an 8-K on Jan 9, 2025, reporting a material agreement and financials.
AI Summary
On January 9, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates significant corporate activity or financial updates for Cyclacel Pharmaceuticals, Inc., which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks.
Key Numbers
- 0-50626 — Commission File Number (SEC File Number for Cyclacel Pharmaceuticals, Inc.)
- 91-1707622 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 (address) — Principal executive office address
FAQ
What specific material definitive agreement was entered into by Cyclacel Pharmaceuticals, Inc. on or before January 9, 2025?
The filing states that an 'Entry into a Material Definitive Agreement' is an item reported, but the specific details of the agreement are not provided in the provided text.
What financial statements or exhibits are included with this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the content of these exhibits is not detailed in the provided text.
What is the primary business of Cyclacel Pharmaceuticals, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
When was Cyclacel Pharmaceuticals, Inc. incorporated?
The company was incorporated in Delaware.
What is the address of Cyclacel Pharmaceuticals, Inc.'s principal executive offices?
The principal executive offices are located at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-10 06:04:16
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Stock Mark
Filing Documents
- tm252869d1_8k.htm (8-K) — 28KB
- tm252869d1_ex10-1.htm (EX-10.1) — 8KB
- 0001104659-25-002198.txt ( ) — 252KB
- cycc-20250109.xsd (EX-101.SCH) — 3KB
- cycc-20250109_def.xml (EX-101.DEF) — 26KB
- cycc-20250109_lab.xml (EX-101.LAB) — 36KB
- cycc-20250109_pre.xml (EX-101.PRE) — 25KB
- tm252869d1_8k_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Addendum to Securities Purchase Agreement, dated as of January 9, 2025, by and between the Company and David Lazar 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 9, 2025 Cyclacel Pharmaceuticals, Inc. By: /s/ David Lazar Name: David Lazar Title: Interim Chief Executive Officer